Corteria
Health Care

Corteria news and milestones

Corteria: 9 headlines on record, 1 headline in the last 90 days. Its story counts 2 milestones.

Data updated Nov 17, 2026 · Back to the company report
9Headlines
1In 90 days
2Milestones

Headlines

Sep 162026
Blog
We are excited to announce that preclinical data on COR-1389, the first-in-class and best-in-class CRF2 receptor agonist, will be presented at EASD 2026 in Milan! COR-1389 is des…
Jul 25, 20252025
Jul 21, 20252025
Blog
COR-1167 is entering Phase 2 clinical trial for the treatment of Worsening Heart Failure after obtaining promising Phase 1 data, while the Phase 1 of COR-1389 is ongoing for the…
Jun 28, 20242024
Blog
At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac f…
Mar 26, 20242024
Blog
Corteria team is very proud to announce the initiation of COR-1167 first-in-human study. COR-1167 is a first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist. A…
Jan 8, 20242024
Blog
Paris (France), 05 January 2024 - Corteria Pharmaceuticals ("Corteria"), a biopharmaceutical company specialized in the development of transformative therapies for heart failure…
Sep 6, 20232023
News · bioworld.com
As part of its quest to advance its three first-in-class heart failure drug candidates toward the clinic, Corteria Pharmaceuticals SAS has closed an oversubscribed €65 million (U…
Sources: the outlets named on each headline, each story once

Milestones

Each milestone is dated by its source: registers, filings, the press

How to cite

Corteria, News. Alion, Nov 17, 2026. https://alion.io/company/corteriapharma/news

.json · .md · CC BY-SA 4.0